Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU
EMA Questions Efficacy Of Eye Drop
Executive Summary
A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.
You may also be interested in...
Novartis's Kedalion Buy Could Revive Prospects For Xiidra
Getting hold of Kedalion's device that delivers topical drugs to the eye with comparable effect but with up to an 80% reduction in dose compared to standard eye drops bodes well for Novartis's ophthalmology business.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Another Divestment By Takeda, To China’s Hasten For $322m
Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.